این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
Veterinary Research Forum، جلد ۱۴، شماره ۶، صفحات ۳۲۳-۳۲۸
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی Development of polyclonal heavy chain antibodies targeting programmed death ligand-1
چکیده انگلیسی مقاله Programmed death ligand-1 (PD-L1, CD274 and B7-H1) has been described as a ligand for immune inhibitory receptor programmed death protein 1 (PD-1). With binding to PD-1 on activated T cells, PD-L1 can prevent T cell responses via motivating apoptosis. Consequently, it causes cancers immune evasion and helps the tumor growth; hence, PD-L1 is regarded as a therapeutic target for malignant cancers. The anti-PD-L1 monoclonal antibody targeting PD-1/PD-L1 immune checkpoint has attained remarkable outcomes in clinical application and has turned to one of the most prevalent anti-cancer drugs. The present study aimed to develop polyclonal heavy chain antibodies targeting PD-L1via Camelus dromedarius immunization. The extra-cellular domain of human PD-L1 (hPD-L1) protein was cloned, expressed, and purified. Afterwards, this recombinant protein was utilized as an antigen for camel immunization to acquire polyclonal camelid sera versus this protein. Our outcomes showed that hPD-L1 protein was effectively expressed in the prokaryotic system. The antibody-based techniques, such as enzyme-linked immunosorbent assay, western blotting, and flow cytometry displayed that the hPD-L1 protein was detected by generated polyclonal antibody. Due to the advantages of multi-epitope-binding ability, our study exhibited that camelid antibody is effective to be applied significantly for detection of PD-L1 protein in essential antibody-based studies.
کلیدواژه‌های انگلیسی مقاله Camelid heavy-chain antibody,Immunization,Polyclonal antibody,Programmed death ligand-1
نویسندگان مقاله Akbar Oghalaie |
Venom and Biotherapeutics Molecules Laboratory, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran

Alireza Shoari |
Venom and Biotherapeutics Molecules Laboratory, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran

Fatemeh Kazemi-Lomedasht |
Venom and Biotherapeutics Molecules Laboratory, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran

Fatemeh Rahimi-Jamnani |
Department of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, Iran

Fereidoun Mahboudi |
Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran

Hajarossadat Ghaderi |
Venom and Biotherapeutics Molecules Laboratory, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran

Mohammad Hosseininejad-Chafi |
Venom and Biotherapeutics Molecules Laboratory, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran

Reza Moaazami |
Human Genetics Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran

Arghavan Ashja Ardalan |
Venom and Biotherapeutics Molecules Laboratory, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran

Somayeh Piri-Gavgani |
Department of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, Iran

Delavar Shabazzadeh |
Venom and Biotherapeutics Molecules Laboratory, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran

Mahdi Behdani |
Venom and Biotherapeutics Molecules Laboratory, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran

نشانی اینترنتی https://vrf.iranjournals.ir/article_702483_87e0f1776ed5c0744a504cf40b94d510.pdf
فایل مقاله فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده en
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات